Latest results from NETTER-1 study presented at BNMS
Imaging Equipment Limited commercial director Jeevan Virk delivers a presentation on the NETTER-1 study at BNMS
Imaging Equipment Limited (IEL) attended the annual British Nuclear Medicine Society’s spring conference at the ICC in Birmingham. It was one of 31 companies exhibiting at the meeting with around 500 delegates from throughout the UK and Europe.
The conference programme was varied to reflect the full range of nuclear medicine disciplines and gave a view of what is current clinical practice in the UK in terms of existing diagnostics and therapy, as well as what is on the horizon. Peptide receptor radionuclide therapy (PRRT) was well represented and there were several specific talks on Lutathera (177Lu-DOTATATE) from centres currently using it in neuroendocrine tumour patient therapy. Consensus of opinion was in favour of PRRT and IEL commercial director Jeevan Virk gave an invited presentation on the latest results of the NETTER-1 study that was well received by the audience.
See the full report on page 23 of the July 2016 issue of RAD Magazine.
